DAY 2: Monday, September 22, 2025
Program subject to change.
07:00 - 18:00
Registration Open
08:30 - 09:30
Plenary Lecture 1: Predicting Altered Drug Disposition in Disease States using Novel In Vitro and Modeling Tools
10:00 - 12:00
Concurrent Symposia 1 & 2
Symposium 1: Transporter-Enzyme Interplay & Drug-Drug Interactions in Health & Disease
Co-chairs: Xiaoyan Chu, Merck, USA; Jacqueline Tiley, University of North Carolina at Chapel Hill, USA
-
This session, featuring speakers from academia and industry, will cover topics on 1) the interplay between drug-metabolizing enzymes and transporters that influence drug pharmacokinetics and DDIs, and how physiologically based pharmacokinetic (PBPK) models can support our understanding of these complex processes, and 2) the effect of disease on enzymes and transporters. Attendees will gain insights into this cutting-edge research and will have a better understanding of current methodologies and challenges in predicting pharmacokinetics and DDIs, and how disease can affect drug efficacy and safety.
Symposium 2: Oral Delivery of bRo5 Compounds
Co-chairs: Simone Schadt, Roche, Switzerland; Donglu Zhang, Genentech, USA
-
Synopsis: In this session, we will explore the challenges and advancements in enhancing the oral bioavailability of beyond rule of five (bRo5) compounds, such as peptides and degraders. These compounds often exhibit poor permeability and solubility, making oral delivery a significant hurdle. Attendees will gain insights from recent case studies and research findings, highlighting successful examples and ongoing efforts in this critical area of drug development.
12:00 - 15:00
Lunch/Exhibits/Poster Viewing/Supplier Showcase
15:00 - 16:30
Concurrent Symposia 3 & 4
Symposium 3: Nuclear Receptors in Drug Discovery and Development
Co-chairs: Huichang (Nancy) Bi, Southern Medical University, China; Taosheng Chen, St. Jude's Children's Research Hospital, USA
-
The human nuclear receptor (NR) superfamily contains 48 members with diverse roles in physiology and disease. NRs are attractive drug targets. Approved NR-targeting therapies have had immense success treating various diseases. Speakers for this session are experts actively working on various members of the NR superfamily by using multidisciplinary approaches such as biology, pharmacology, medicinal chemistry and structural biology.
Symposium 4: Protein-based and Novel Modalities
Co-chairs: David Belair, Abbvie, USA; Nita Patel, Eli Lilly, USA
-
This session will highlight the importance of understanding the disposition and behavior of various drugs that use antibodies to facilitate their targeting. Novel modalities such as antibody-drug conjugates, RNA conjugates, or protein degraders will be discussed. The presentations will focus on overcoming ADME challenges of antibody conjugates, mechanistic PKPD modeling of degraders and translational modeling of integrated molecular and ADME kinetics for next-generation ADCs.
16:45 - 18:15
Debate Session
Motion: This house believes that cutting-edge in silico tools, in vitro studies, and artificial intelligence will make preclinical in vivo studies in animals obsolete within the next decade
Moderator: Andreas Reichel, Bayer, Germany